Skip to main content


Fig. 2 | Cancer Cell International

Fig. 2

From: Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment

Fig. 2

MTA treatment increases mitochondrial mass of lung cancer A549 cells. a Changes in mitochondrial mass after treatment with 1 µM MTA were quantified by FACS analysis. In detail, to quantify changes in mitochondrial mass, a gate was set so 5% of untreated A549 cells (24 h) were scored as positive for mitochondrial mass (see Additional file 4: Figure. S3 for details). The same gate was applied to all samples. The total population of cells was further divided into two subpopulations according to their respective DNA content, e.g. G1-phase cells and S/G2/M-phase cells. Shown are the mean values and the standard error of mean, N = 4. p value was determined by unpaired and two-tailed Student’s t test, *p < 0.05, **p = 0.0076. b Cell cycle distribution after MTA treatment. G1- and S/G2/M-phase gates were adjusted for each sample to compensate for slight shifts in linear DAPI fluorescence intensity due to treatment-induced changes in FSC/SSC signal intensity. c Analysis of parental A549 cell protein expression after MTA treatment by western blot. G2M cell cycle checkpoint proteins: Cyclin B1, Cdc2 and p-Cdc2Tyr15. DNA damage response protein: p-H2AXSer139. Signal intensities were normalized to the internal control (β-actin) on the same blot. The control condition, i.e. untreated A549 cells (24 h), was set to unity. d MTA treatment for 48 h induced morphological changes in parental A549 cells

Back to article page